Navigation Links
CV Therapeutics and Medlogics Device Corporation Sign Licensing Agreement for CVT's Innovative Stent Coating Technology
Date:2/4/2008

velopment and manufacturing at this facility. The company plans to launch its COBRA stent in Europe in the 1st quarter of 2008.

Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including operating losses and fluctuations in operating results; capital requirements; regulatory review and approval of our products; special protocol assessment agreement; the conduct and timing of clinical trials; commercialization of products; market acceptance of products; product labeling; concentrated customer base; reliance on strategic partnerships and collaborations; uncertainties in drug development; uncertainties regarding intellectual property; and other risks detailed from time to time in CV Therapeutics' SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2007. CV Therapeutics disclaims any intent or obligation to update these forward-looking statements.


'/>"/>
SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Inflamax scientists worked closely with internationally ... the study, which will provide critical insight into ... in the study of allergy treatments, the Environmental ... models. Although both the models are well recognized ... direct comparison between the allergic responses evoked by ...
(Date:5/21/2013)... 21, 2013 PathoGenetix, Inc., a commercial-stage ... typing, announced today that it has successfully identified and ... strains obtained from the Centers for Disease Control and ... technology. The findings are detailed in a poster ... Society for Microbiology in Denver on Monday. , The ...
(Date:5/20/2013)... (PRWEB) May 21, 2013 Grace ... specializing in “game-changing” life science and health related private ... Dergham to its International Project Team. Dergham's expertise in ... greater multi-cultural depth to Grace Century as it continues ... globe. , Ms. Dergham holds both an under graduate ...
(Date:5/20/2013)... Calif. , May 20, 2013  (PSHR) ... providing naturally based products across a broad range ... company has retained investor relations firm, BlueWater Advisory ... the return to trading process, and to direct ... trading initiation. Matthew Mills ...
Breaking Biology Technology:Inflamax Research selected by the Immune Tolerance Network and the National Institutes of Health to conduct a landmark clinical study on the underlying mechanisms of allergic inflammation. 2New Genotyping System Identifies Pathogenic E. coli Outbreak Strains 2New Genotyping System Identifies Pathogenic E. coli Outbreak Strains 3Dalia Dergham Joins Grace Century FZ LLC International Project Team 2Pacific Shore Holdings Retains Investor Relations Firm 2
... Aug. 23 Monogram,Biosciences, Inc. (Nasdaq: MGRM ) ... scheduled to present a corporate overview at the Thomas,Weisel ... 3:15 p.m. (Eastern Time) at the Four Seasons Hotel ... or the subsequent archived,recording, log on to http://www.monogrambio.com ...
... Conn., Aug. 22 Biodel, Inc. (Nasdaq:,BIOD) ... M.D., to its,Scientific Advisory Board (SAB). ... President of Research,and Development at Kos Pharmaceuticals, ... until Kos was acquired by Abbott Laboratories. ...
... ZymoGenetics, Inc. (Nasdaq:,ZGEN) announced that the company ... update on the regulatory review of recombinant thrombin,(rThrombin). ... on August 22 at 5:00,p.m. Eastern Time by ... the call approximately 10 minutes prior to,the scheduled ...
Cached Biology Technology:Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007 2Ralf Rosskamp, M.D. Joins Biodel's Scientific Advisory Board 2Ralf Rosskamp, M.D. Joins Biodel's Scientific Advisory Board 3ZymoGenetics Will Hold Conference Call Today at 5:00 p.m. Eastern Time to Provide Update on rThrombin 2
(Date:5/21/2013)... in shape is an uphill battle? Try staying fit ... weightlessness withers muscle and bone. , That,s the challenge ... with a new three-year, $1.2 million grant from NASA. ... during multiyear exploratory missions. , "You could give astronauts ... can,t get them to stick to it, it isn,t ...
(Date:5/21/2013)... Where? Copenhagen, Denmark: Bella Center Congress Centre ... , Why? An annual meeting focusing ... manufacturing and installation, drawing on leading experiences from all ... from a record of more than 900 abstracts received ... and oral presentations, more than 460 visual presentation, 55 ...
(Date:5/21/2013)... way genes function without changing the underlying DNA ... of pregnant women during any trimester, potentially providing ... weeks after giving birth, and an opportunity to ... of the small study involving 52 pregnant women ... Psychiatry . , "Postpartum depression can be harmful ...
Breaking Biology News(10 mins):Fueling fitness on the final frontier 221st European Biomass Conference and Exhibition 221st European Biomass Conference and Exhibition 321st European Biomass Conference and Exhibition 4Genetic predictors of postpartum depression uncovered by Hopkins researchers 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 3
... Fish become feisty but fearful when facing themselves in ... like something they don,t understand," said Julie Desjardins, a post-doctoral ... be published in Biology Letters describing the study. ... is just so far outside their realm of experience that ...
... of life" has been constructed by researchers at ... for the gamma-proteobacteria, a large group of medically ... Salmonella typhimurium, and other disease-causing organisms.* By building ... identify similarities and differences between the make-up of ...
... A research collaboration lead by a professor from ... work to develop methods to protect agriculturally important crops ... with the support of a $1.45 million award from ... sponsored by the National Science Foundation (NSF) and the ...
Cached Biology News:Fish facing reflections become feisty but fearful 2Fish facing reflections become feisty but fearful 3New 'Tree of Life' established for one of the largest groups of bacteria 2New 'Tree of Life' established for one of the largest groups of bacteria 3Plant protection research targets cacao in developing countries 2
Biotin anti-mouse Ly-49C/F/I/H...
... Purified Tyrosine Hydroxylase (Ser40) Polyclonal ... raised against synthetic phosphopeptide corresponding ... the phospho-Ser40 of rat Tyrosine ... purified by sequential chromatography on ...
Mouse Wnt-9b Biotinylated Affinity Purified PAb ENTREZ GeneID: 22412...
NF kappa B Related Sampler Kit 10g each...
Biology Products: